Please login to the form below

Perspective on biotech

In this supplementary issue of Perspective, we reveal the emerging technologies taking the biotech world by storm and ask if the definition of a biotech organisation needs updating.
Biotech companies operate in highly complex markets with extremely challenging regulatory constraints. As a creative marketing consultancy we are well positioned to cut through this noise and tackle challenges from all angles, offering leading strategic and creative solutions. 

Ahead of our upcoming report into strategic challenges and opportunities in the sector, we have been speaking to biotech experts to find out their perspective on the state of the industry. 

Here we explore some of their enlightening insights and reveal how the definition of biotech is changing as big pharma turns its research and development to biological therapies. 

Find out about: 

  • The emerging technologies revolutionising the biotech industry – from immunotherapy breakthroughs to cutting-edge gene editing techniques
  • How to define a biotech company – is the current definition still valid?
  • Shaping the future of healthcare – solving four common challenges facing biotech companies today.



Download the supplement from Blue Latitude Health

26th September 2017

Share

Tags

Company Details

Blue Latitude Health

+44 203 328 1840

Contact Website

Address:
Blue Latitude Health (UK)
140 Aldersgate Street
London
EC1A 4HY
United Kingdom

Latest content on this profile

Three strategies for managing loss of exclusivity successfully
Consultant, Claire Taylor explains why you should be strategically planning your LOE strategy years in advance.
Blue Latitude Health
What does the future hold for Medical Affairs?
Lori Lush, Head of Fishawack Medical, reveals why she’s driven to tell impactful scientific stories, the benefits of cross-functional collaboration, and the trends she predicts for the next five years.
Blue Latitude Health
Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the life sciences industry can do to rebuild trust.
Blue Latitude Health
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and Senior Consultant Craig Moore explore the benefits of using real-world evidence and the common pitfalls life science companies should avoid.
Blue Latitude Health
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of this lost time for patients?
Blue Latitude Health
Unpacking rare diseases in the first edition of Delta magazine
Fishawack Health launches Delta magazine with a deep dive into rare disease commercialization
Blue Latitude Health